Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fennec Pharmaceuticals (FENC) Revenue (2020 - 2025)

Fennec Pharmaceuticals' Revenue history spans 6 years, with the latest figure at $13.8 million for Q4 2025.

  • For the quarter ending Q4 2025, Revenue rose 73.84% year-over-year to $13.8 million, compared with a TTM value of $44.6 million through Dec 2025, down 6.09%, and an annual FY2025 reading of $44.6 million, down 6.09% over the prior year.
  • Revenue for Q4 2025 was $13.8 million at Fennec Pharmaceuticals, up from $12.5 million in the prior quarter.
  • The five-year high for Revenue was $25.4 million in Q1 2024, with the low at -$914000.0 in Q4 2022.
  • Average Revenue over 5 years is $6.2 million, with a median of $6.7 million recorded in 2023.
  • Year-over-year, Revenue plummeted 533.33% in 2022 and then surged 5933.33% in 2023.
  • Tracing FENC's Revenue over 5 years: stood at -$55000.0 in 2021, then plummeted by 1561.82% to -$914000.0 in 2022, then skyrocketed by 1165.1% to $9.7 million in 2023, then dropped by 18.59% to $7.9 million in 2024, then soared by 73.84% to $13.8 million in 2025.
  • Per Business Quant, the three most recent readings for FENC's Revenue are $13.8 million (Q4 2025), $12.5 million (Q3 2025), and $9.7 million (Q2 2025).